COVID-19 may solidify Australian biotech Mesoblast Limited’s position at the forefront of the development of stem cell therapies as FDA-regulated biologic products, giving a potential second use for the company’s lead allogeneic mesenchymal stem cell (MSC) therapy, Ryoncil (remestemcel-L).
Mesoblast, Athersys Take Lead In Race To Develop Stem Cell Therapies For COVID-19
Phase II/III studies are underway for Mesoblast’s remestemcel-L and Athersys’ Multistem, followed by a pack of earlier-stage stem cell candidates from Pluristem, Hope Bioscience and Celltex – with an interactive chart of the COVID-19 cell therapy pipeline.